IGF-1 LR3 vs LL-37 (Cathelicidin)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
IGF-1 LR3
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with extended half-life and enhanced potency. The modifications prevent binding to IGF binding proteins, increasing bioavailability.
Full details →LL-37 (Cathelicidin)
LL-37 is the only human cathelicidin antimicrobial peptide. It plays crucial roles in innate immunity and has shown diverse biological activities including antimicrobial, immunomodulatory, and wound healing properties.
Full details →Side-by-Side Comparison
| Aspect | IGF-1 LR3 | LL-37 (Cathelicidin) |
|---|---|---|
| Mechanism | Binds to IGF-1 receptors to promote protein synthesis, muscle growth, and fat metabolism. The LR3 modification (13 amino acid extension and arginine substitution) extends half-life from minutes to 20-30 hours. | Disrupts bacterial membranes, neutralizes endotoxins, modulates immune cell function, and promotes wound healing. Has both direct antimicrobial and immunomodulatory effects. |
| Typical Dosage | Research protocols typically use 20-100mcg daily, often divided into multiple injections or administered bilaterally to target muscles. | Research protocols vary widely. Typical ranges: 50-200mcg administered subcutaneously 2-3 times weekly. Some protocols use higher doses for acute infections. |
| Administration | Intramuscular injection (site-specific growth) or subcutaneous for systemic effects. Often cycled 4-6 weeks on, equal time off. | Subcutaneous injection. Can cause significant injection site reactions. Often used in conjunction with other immune-supporting protocols. |
| Side Effects | Hypoglycemia, joint pain, water retention, potential jaw/hand growth with extended use, and injection site reactions. | Injection site pain and reactions are common. May cause flu-like symptoms, temporary fatigue, or immune activation responses. |
| Best For |
What They Have in Common
IGF-1 LR3, LL-37 (Cathelicidin) are both commonly used for:
Key Differences
Unique to IGF-1 LR3:
Detailed Analysis
Commonalities
Both IGF-1 LR3 and LL-37 (Cathelicidin) are commonly used for Recovery & Healing.
Which Should You Choose?
Both peptides have similar evidence levels for their shared goals. Your choice may depend on specific use case, availability, or personal response.
Ready to Learn More?
Looking for trusted sources?